Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xylogic is a Polish pharmaceutical company specializing in the development and distribution of aesthetic medicine and dermo-cosmetic products. Founded in 2006, the company established itself as a leader in the Central and Eastern European dermatology market through its flagship brand, Retix.C, which focuses on retinol-based anti-aging solutions. In 2015, Xylogic was acquired by the French healthcare leader Urgo Group (specifically integrated into Urgo Medical), expanding its reach into international markets. The company's portfolio includes professional chemical peels, specialized serums, and post-treatment home care products designed to address skin conditions such as hyperpigmentation, photoaging, and acne.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xylog.